Alpha Tau Medical’s (DRTS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Alpha Tau Medical (NASDAQ:DRTS) in a report issued on Monday morning,Benzinga reports. HC Wainwright currently has a $9.00 target price on the stock. HC Wainwright also issued estimates for Alpha Tau Medical’s FY2025 earnings at ($0.53) EPS.

Alpha Tau Medical Stock Performance

NASDAQ:DRTS opened at $2.60 on Monday. The stock has a 50-day simple moving average of $3.23 and a 200 day simple moving average of $2.79. Alpha Tau Medical has a 52-week low of $1.75 and a 52-week high of $4.39. The company has a market cap of $181.80 million, a PE ratio of -6.05 and a beta of 0.87.

Alpha Tau Medical (NASDAQ:DRTS) last released its quarterly earnings results on Wednesday, March 12th. The company reported ($0.13) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.13). On average, research analysts predict that Alpha Tau Medical will post -0.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alpha Tau Medical

A number of large investors have recently modified their holdings of DRTS. Levin Capital Strategies L.P. raised its holdings in Alpha Tau Medical by 2.3% during the fourth quarter. Levin Capital Strategies L.P. now owns 314,514 shares of the company’s stock worth $975,000 after acquiring an additional 7,189 shares in the last quarter. Northern Trust Corp increased its position in shares of Alpha Tau Medical by 112.6% during the 4th quarter. Northern Trust Corp now owns 48,666 shares of the company’s stock worth $151,000 after purchasing an additional 25,770 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of Alpha Tau Medical by 188.7% in the 4th quarter. Renaissance Technologies LLC now owns 41,000 shares of the company’s stock valued at $127,000 after buying an additional 26,800 shares during the last quarter. 2.65% of the stock is currently owned by institutional investors and hedge funds.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.